

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058873 A1

(51) International Patent Classification⁷: **C07D 401/14**,
A61K 31/4184, C07D 417/14, A61P 11/00, 31/12

(74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, Gen-
eraal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(21) International Application Number:
PCT/EP2004/053606

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
20 December 2004 (20.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03104802.8 18 December 2003 (18.12.2003) EP
60/566,835 30 April 2004 (30.04.2004) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **TI-BOTEC PHARMACEUTICALS LTD.** [IE/IE]; Little Island, Co Cork (IE).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BONFANTI, Jean-François** [FR/FR]; 4 bis Route Nationale, F-27430 André (FR). **ANDRIES, Koenraad, Jozef, Lodewijk** [BE/BE]; Oosteneinde 9, B-2340 Beerse (BE). **JANSSENS, Frans, Eduard** [BE/BE]; Tinststraat 79, B-2820 Bonheiden (BE). **SOMMEN, François, Maria** [BE/BE]; Langenberg 49, B-2323 Wortel (BE). **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; 51bis, route de Muids, F-27430 André (FR). **LACRAMPE, Jean, Fernand, Armand** [FR/FR]; 15, chemin du Pont de l'Arche, F-76240 Le Mesnil-Esnard (FR).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,

[Continued on next page]

(54) Title: PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION



(57) Abstract: The present invention concerns piperidine-amino-benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I) their prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms wherein Q is C₁₋₆alkyl optionally substituted with trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, C₁₋₄alkylthio, Ar²-oxy-, Ar²-thio-, Ar²(CH₂)_noxy, Ar²(CH₂)_nthio, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, Ar²carbonyl, C₁₋₄alkoxycarbonyl, Ar²(CH₂)_ncarbonyl, aminocarbonyloxy, C₁₋₄alkylcarbonyloxy, Ar²carbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxy carbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyloxy, aminosulfonyl, mono-odi(C₁₋₄alkyl)aminosulfonyl or a heterocycles selected from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₆alkyl; G is a direct bond or optionally substituted C₁₋₁₀ alkanediyl; R¹ is Ar¹ or a monocyclic or bicyclic heterocycle; one of R^{2a} and R^{3a} is C₁₋₆alkyl and the other one of R^{2a} and R^{3a} is hydrogen; in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C₁₋₆alkyl, and R^{3b} is hydrogen; in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C₁₋₆alkyl, and R^{2b} is hydrogen; t is 1, 2 or 3; Ar¹ is phenyl or substituted phenyl; and Ar² is phenyl or substituted phenyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.



NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

The present invention is concerned with piperidine-amino-benzimidazole derivatives
5 having antiviral activity, in particular, having an inhibitory activity on the replication of
the respiratory syncytial virus (RSV). It further concerns the preparation thereof and
compositions comprising these compounds.

Human RSV or Respiratory Syncytial Virus is a large RNA virus, member of the
10 family of Paramyxoviridae, subfamily pneumoviridae together with bovine RSV virus.
Human RSV is responsible for a spectrum of respiratory tract diseases in people of all
ages throughout the world. It is the major cause of lower respiratory tract illness during
infancy and childhood. Over half of all infants encounter RSV in their first year of life,
and almost all within their first two years. The infection in young children can cause
15 lung damage that persists for years and may contribute to chronic lung disease in later
life (chronic wheezing, asthma). Older children and adults often suffer from a (bad)
common cold upon RSV infection. In old age, susceptibility again increases, and RSV
has been implicated in a number of outbreaks of pneumonia in the aged resulting in
significant mortality.

20 Infection with a virus from a given subgroup does not protect against a subsequent
infection with an RSV isolate from the same subgroup in the following winter season.
Re-infection with RSV is thus common, despite the existence of only two subtypes, A
and B.


25 Today only three drugs have been approved for use against RSV infection. A first one
is ribavirin, a nucleoside analogue, provides an aerosol treatment for serious RSV
infection in hospitalized children. The aerosol route of administration, the toxicity (risk
of teratogenicity), the cost and the highly variable efficacy limit its use. The other two
30 drugs, RespiGam® and palivizumab, polyclonal and monoclonal antibody
immunostimulants, are intended to be used in a preventive way.

Other attempts to develop a safe and effective RSV vaccine have all met with failure
thus far. Inactivated vaccines failed to protect against disease, and in fact in some cases
35 enhanced disease during subsequent infection. Live attenuated vaccines have been tried
with limited success. Clearly there is a need for an efficacious non-toxic and easy to
administer drug against RSV replication.

Several series of benzimidazolyl and imidazopyridinyl piperidines have been described in patents, patent applications and publications of Janssen Pharmaceutica N.V. as compounds possessing antihistaminic properties. See for example EP-A-5 318, EP-A-99 139, EP-A-145 037, WO-92/01687, Janssens F. et al. in Journal of Medicinal Chemistry, Am. Chem. Soc., Vol. 28, no. 12, pp. 1934-1943 (1985).

Benzimidazoles and imidazopyridines as inhibitors of RSV replication have been described in WO 01/00611, WO 01/00612 and WO 01/00615.

The present invention concerns inhibitors of RSV replication, which can be represented by formula (I)











their prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms wherein

- Q is C₁₋₆alkyl optionally substituted with one or more substituents each independently selected from the group consisting of trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, C₁₋₄alkylthio, Ar²-oxy-, Ar²-thio-, Ar²(CH₂)_noxy, Ar²(CH₂)_nthio, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, Ar²carbonyl, C₁₋₄alkoxycarbonyl, Ar²(CH₂)_ncarbonyl, aminocarbonyloxy, C₁₋₄alkylcarbonyloxy, Ar²carbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyloxy, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₆alkyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from the group consisting of amino, mono- and diC₁₋₄alkylamino and Ar²-C₁₋₄alkylamino and the other substituent is selected from the group consisting of carboxyl, C₁₋₆alkyloxycarbonyl, Ar²-C₁₋₄alkyloxycarbonyl, aminocarbonyl and aminosulfonyl;
- G is a direct bond or C₁₋₁₀alkanediyl optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, C₁₋₆alkyloxy, Ar¹C₁₋₆alkyloxy, C₁₋₆alkylthio, Ar¹C₁₋₆alkylthio,

$\text{HO}(-\text{CH}_2-\text{CH}_2-\text{O})_n-$, $\text{C}_{1-6}\text{alkyloxy}(-\text{CH}_2-\text{CH}_2-\text{O})_n-$ and
 $\text{Ar}^1\text{C}_{1-6}\text{alkyloxy}(-\text{CH}_2-\text{CH}_2-\text{O})_n-$;

R^1 is Ar^1 or a monocyclic or bicyclic heterocycle being selected from piperidinyl,
 piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro-
 furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl,
 isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl,
 benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl,
 1*H*-imidazo[4,5-*b*]pyridinyl, 3*H*-imidazo[4,5-*b*]pyridinyl, imidazo[1,2-*a*]-
 pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridyl or a radical of formula



;

wherein each of said monocyclic or bicyclic heterocycles may optionally be substituted
 with 1 or where possible more, such as 2, 3, 4 or 5, substituents individually
 selected from the group of substituents consisting of halo, hydroxy, amino, cyano,
 carboxyl, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkyloxy}$, $\text{C}_{1-6}\text{alkylthio}$, $\text{C}_{1-6}\text{alkyloxyC}_{1-6}\text{alkyl}$, Ar^1 ,
 $\text{Ar}^1\text{C}_{1-6}\text{alkyl}$, $\text{Ar}^1\text{C}_{1-6}\text{alkyloxy}$, hydroxy $\text{C}_{1-6}\text{alkyl}$, mono-or di($\text{C}_{1-6}\text{alkyl}$)amino,
 mono-or di($\text{C}_{1-6}\text{alkyl}$)amino $\text{C}_{1-6}\text{alkyl}$, polyhalo $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkylcarbonylamino}$,
 $\text{C}_{1-6}\text{alkyl-SO}_2\text{-NR}^{4a}$, $\text{Ar}^1\text{-SO}_2\text{-NR}^{4a}$, $\text{C}_{1-6}\text{alkyloxycarbonyl}$, $-\text{C}(=\text{O})\text{-NR}^{4a}\text{R}^{4b}$,
 $\text{HO}(-\text{CH}_2-\text{CH}_2-\text{O})_n-$, halo($-\text{CH}_2-\text{CH}_2-\text{O})_n-$, $\text{C}_{1-6}\text{alkyloxy}(-\text{CH}_2-\text{CH}_2-\text{O})_n-$,
 $\text{Ar}^1\text{C}_{1-6}\text{alkyloxy}(-\text{CH}_2-\text{CH}_2-\text{O})_n-$ and mono-or di($\text{C}_{1-6}\text{alkyl}$)amino($-\text{CH}_2-\text{CH}_2-\text{O})_n-$;
 each n independently is 1, 2, 3 or 4;
 one of R^{2a} and R^{3a} is $\text{C}_{1-6}\text{alkyl}$ and the other one of R^{2a} and R^{3a} is hydrogen;

in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C_{1-6} alkyl, and R^{3b} is hydrogen;

in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C_{1-6} alkyl, and R^{2b} is hydrogen; or

5 R^{3b} is C_{1-6} alkyl; and R^{3a} , R^{2a} , R^{2b} all are hydrogen; or

R^{2b} is C_{1-6} alkyl; and R^{3a} , R^{2a} , R^{3b} all are hydrogen;

R^{4a} and R^{4b} can be the same or can be different relative to one another, and are each independently hydrogen or C_{1-6} alkyl; or

R^{4a} and R^{4b} taken together may form a bivalent radical of formula $-(CH_2)_s-$;

10 R^5 is hydrogen or C_{1-6} alkyl;

m is 1 or 2;

p is 1 or 2;

s is 4 or 5;

t is 1, 2 or 3;

15 Ar^1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, polyhalo C_{1-6} alkyl, and C_{1-6} alkyloxy;

Ar^2 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from the group consisting of halo, hydroxy, amino, cyano, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, polyhalo C_{1-6} alkyl, amino C_{1-6} alkyl, C_{1-6} alkyloxy, aminosulfonyl, aminocarbonyl, hydroxycarbonyl, C_{1-4} alkylcarbonyl, mono- or di(C_{1-4} alkyl)amino, mono- or di(C_{1-4} alkyl)aminocarbonyl, mono- or di(C_{1-4} alkyl)aminosulfonyl, mono- or di(C_{1-4} alkyl)amino C_{1-6} alkyl and C_{1-4} alkoxycarbonyl.

25

The invention further relates to the use of a compound of formula (I), or a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex and stereochemically isomeric form thereof, for the manufacture of a medicament for inhibiting RSV replication. Or the invention relates to a method of inhibiting RSV replication in a warm-blooded animal said method comprising the administration of an effective amount of a compound of formula (I), or a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex and stereochemically isomeric form thereof.

30

In a further aspect, this invention relates to novel compounds of formula (I) as well as methods for preparing these compounds.

35

The term 'prodrug' as used throughout this text means the pharmacologically acceptable derivatives, e.g. esters and amides, such that the resulting biotransformation

product of the derivative is the active drug as defined in the compounds of formula (I). The reference by Goodman and Gilman (The Pharmacological Basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs", p. 13-15) describing prodrugs generally, is hereby incorporated. Prodrugs are characterized by a good aqueous solubility and bioavailability, and are readily metabolized into the active inhibitors *in vivo*.

The terms 'C₁₋₆alkyl optionally substituted with one or more substituents' such as used in the definition of Q, or 'C₁₋₁₀alkanediyl optionally substituted with one or more substituents' as used in the definition of G are meant to comprise C₁₋₆alkyl radicals respectively C₁₋₁₀alkanediyl radicals having no, one, two or more substituents, for example no, one, two, three, four, five or six substituents, in particular no, one, two or three substituents, further in particular no, one or two substituents. The upper limit of the number of substituents is determined by the number of hydrogen atoms that can be replaced as well as by the general properties of the substituents such as their bulkiness, these properties allowing the skilled person to determine said upper limit.

As used in the foregoing and hereinafter, 'polyhaloC₁₋₆alkyl' as a group or part of a group, e.g. in polyhaloC₁₋₆alkyloxy, is defined as mono- or polyhalo substituted C₁₋₆alkyl, in particular C₁₋₆alkyl substituted with up to one, two, three, four, five, six, or more halo atoms, such as methyl or ethyl with one or more fluoro atoms, for example, difluoromethyl, trifluoromethyl, trifluoroethyl. Also included are perfluoro C₁₋₆alkyl groups, which are C₁₋₆alkyl groups wherein all hydrogen atoms are replaced by fluoro atoms, e.g. pentafluoroethyl. In case more than one halogen atom is attached to an alkyl group within the definition of polyhaloC₁₋₄alkyl, the halogen atoms may be the same or different.

Each of the monocyclic or bicyclic heterocycles in the definition of R¹ may optionally be substituted with 1 or where possible more substituents, such as 2, 3, 4 or 5, substituents. In particular, said heterocycles may optionally be substituted with up to 4, up to 3, up to 2 substituents, or up to 1 substituent.

Each Ar¹ or Ar² may be unsubstituted phenyl or phenyl substituted with 1 or more substituents, such as 5 or 4 substituents or, which is preferred, up to 3 substituents, or up to two substituents, or with one substituent.

A hydroxyC₁₋₆alkyl group when substituted on an oxygen atom or a nitrogen atom preferably is a hydroxyC₂₋₆alkyl group wherein the hydroxy group and the oxygen or nitrogen is separated by at least two carbon atoms.

As used herein C₁₋₃alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl and the like; C₁₋₄alkyl as a group or part of a group defines
5 straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the group defined for C₁₋₃alkyl and butyl and the like; C₂₋₄alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 2 to 4 carbon atoms such as ethyl, propyl, 1-methylethyl, butyl and the like; C₁₋₆alkyl as a group or part of a group defines straight or branched chain
10 saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C₁₋₄alkyl and pentyl, hexyl, 2-methylbutyl and the like; C₁₋₉alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 9 carbon atoms such as the groups defined for C₁₋₆alkyl and heptyl, octyl, nonyl, 2-methylhexyl, 2-methylheptyl and the like; C₁₋₁₀alkyl as a group or part
15 of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms such as the groups defined for C₁₋₉alkyl and decyl, 2-methylnonyl and the like.

C₃₋₇cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
20 cycloheptyl.

C₂₋₅alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 2 to 5 carbon atoms such as, for example, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,5-pentanediyl and
25 the like; C₁₋₄alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl and the like; C₁₋₆alkanediyl is meant to include C₁₋₄alkanediyl and the higher homologues thereof having from 5 to 6 carbon atoms such as, for example, 1,5-pentanediyl, 1,6-hexanediyl and the like;
30 C₁₋₁₀alkanediyl is meant to include C₁₋₆alkanediyl and the higher homologues thereof having from 7 to 10 carbon atoms such as, for example, 1,7-heptanediyl, 1,8-octanediyl, 1,9-nonanediyl, 1,10-decanediyl and the like.

As used herein before, the term (=O) forms a carbonyl moiety when attached to a
35 carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom. The term (=N-OH) forms a hydroxylimine moiety when attached to a carbon atom.

The term 'halo' is generic to fluoro, chloro, bromo and iodo.

It should be noted that the radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable.

5

Radicals used in the definitions of the variables include all possible isomers unless otherwise indicated. For instance pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.

- 10 When any variable occurs more than one time in any constituent, each definition is independent.

- Whenever used hereinafter, the terms 'compounds of formula (I)', or 'the present compounds' or similar terms are meant to include the compounds of general formula (I), their prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms. An interesting subgroup of the compounds of formula (I) or any subgroup thereof are the *N*-oxides, salts and all the stereoisomeric forms of the compounds of formula (I).

- 20 It will be appreciated that some of the compounds of formula (I) may contain one or more centers of chirality and exist as stereochemically isomeric forms.

- The term "stereochemically isomeric forms" as used hereinbefore defines all the possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess.

- Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

- 35 Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term 'stereoisomerically pure' concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum

10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a
5 stereoisomeric excess of 97% up to 100%. The terms 'enantiomerically pure' and 'diastereomerically pure' should be understood in a similar way, but then having regard to the enantiomeric excess, respectively the diastereomeric excess of the mixture in question.

10 Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyl-tartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Alternatively, enantiomers
15 may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These
20 methods will advantageously employ enantiomerically pure starting materials.

The diastereomeric racemates of formula (I) can be obtained separately by conventional methods. Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column
25 chromatography.

For some of the compounds of formula (I), their prodrugs, N-oxides, salts, solvates, quaternary amines, or metal complexes and the intermediates used in the preparation thereof, the absolute stereochemical configuration was not experimentally determined.
30 A person skilled in the art is able to determine the absolute configuration of such compounds using art-known methods such as, for example, X-ray diffraction.

The present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but
35 different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

For therapeutic use, salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases, which are

non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

- 5 The pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (I) are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids
- 10 such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic (i.e. hydroxybutanedioic acid), tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic,
- 15 salicylic, *p*-aminosalicylic, pamoic and the like acids.

Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

- 20 The compounds of formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the
- 25 benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

- The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates
- 30 are for example hydrates, alcoholates and the like.

- The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as,
- 35 for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyl iodide or benzyl iodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl *p*-toluenesulfonates. A quaternary amine has a positively charged nitrogen.


Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.

The *N*-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide.

It will be appreciated that the compounds of formula (I) may have metal binding, chelating, complexing properties and therefore may exist as metal complexes or metal chelates. Such metalated derivatives of the compounds of formula (I) are intended to be included within the scope of the present invention.


Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

One embodiment of the present invention concerns compounds of formula (I-a):



wherein Q, t, R⁵, G and R¹ are as specified above in the definitions of the compounds of formula (I) or as in any of the subgroups of compounds (I) specified herein; and
 R^{2a} is C₁₋₆alkyl;
 R^{2b} is hydrogen or C₁₋₆alkyl.


Another embodiment of the present invention concerns compounds of formula (I-b):



wherein Q, t, R⁵, G and R¹ are as specified above in the definitions of the compounds of formula (I) or as in any of the subgroups of compounds (I) specified herein; and
 R^{3a} is C₁₋₆alkyl;
 R^{3b} is hydrogen or C₁₋₆alkyl.

Another embodiment of the present invention concerns compounds of formula (I-c):




-11-



wherein Q, t, R⁵, G and R¹ are as specified above in the definitions of the compounds of formula (I) or as in any of the subgroups of compounds (I) specified herein; and R^{3b} is C₁₋₆alkyl.

5

Still further embodiments comprise compounds of formula (I-a), (I-b) or (I-c) wherein t = 2, i.e. compounds of formulae



10

wherein Q, R⁵, G, R¹, R^{2a}, R^{2a}, R^{3a}, R^{3b} are as specified above in the definitions of the compounds of formula (I) or as in any of the subgroups of compounds (I) specified herein.

15 It is to be understood that the above defined subgroups of compounds of formulae (I-a), (I-b), etc. as well as any other subgroup defined herein, are meant to also comprise any prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms of such compounds.

Particular subgroups of the compounds of formula (I) are those compounds of formula (I), or any subgroup of compounds of formula (I) specified herein, wherein G is C₁₋₁₀alkanediyl, more in particular wherein G is methylene.

- 5 Other particular subgroups of the compounds of formula (I) are those compounds of formula (I), or any subgroup of compounds of formula (I) specified herein, wherein
- (a) R¹ is other than Ar¹; or wherein
 - (b) R¹ is Ar¹ or a monocyclic heterocycle, which is as specified in the definitions of the compounds of formula (I) or any of the subgroups thereof.


10

Further particular subgroups of the compounds of formula (I) are those compounds of formula (I), or any subgroup of compounds of formula (I) specified herein, wherein

- (c) R¹ is pyridyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halo, hydroxy, amino, cyano, carboxyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, Ar¹, Ar¹C₁₋₆alkyl, Ar¹C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)amino, mono- or di(C₁₋₆alkyl)amino-C₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{4a}-, Ar¹-SO₂-NR^{4a}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{4a}R^{4b}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono- or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-; or more in particular
- (d) R¹ is pyridyl substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy, C₁₋₆alkyl, halo, C₁₋₆alkyloxy, Ar¹C₁₋₆alkyloxy and (C₁₋₆alkyloxy)C₁₋₆alkyloxy; preferably wherein
- (e) R¹ is pyridyl substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy, C₁₋₆alkyl, halo and C₁₋₆alkyloxy; or wherein
- (f) R¹ is pyridyl substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy and C₁₋₆alkyl; more preferably wherein
- (g) R¹ is pyridyl substituted with hydroxy and C₁₋₆alkyl; or more preferably wherein
- (h) R¹ is pyridyl substituted with hydroxy and methyl; or wherein
- (i) R¹ is 3-hydroxy-6-methylpyrid-2-yl.

Further embodiments comprise those compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein

- (j) R¹ is Ar¹, quinolinyl, benzimidazolyl, a radical of formula



(c-4)

35

pyrazinyl, or pyridyl; or wherein

(k) R^1 is Ar^1 , quinolinyl, benzimidazolyl or a radical of formula (c-4) wherein m is 2, pyrazinyl, or pyridyl;

5 wherein each of the radicals in (j) and (k) may optionally be substituted with the substituents specified in the definition of the compounds of formula (I) and in particular pyridyl may be substituted as specified above in (a) to (i).

Further embodiments comprise those compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein

- 10 (l) R^1 is Ar^1 , quinolinyl, benzimidazolyl or a radical of formula (c-4) wherein m is 2, pyrazinyl, or pyridyl, wherein each of these radicals may optionally be substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, Ar^1C_{1-6} alkyloxy, $(C_{1-6}$ alkyloxy) C_{1-6} alkyloxy; or more specifically wherein
- 15 (m) R^1 is Ar^1 , quinolinyl, benzimidazolyl or a radical of formula (c-4) wherein m is 2, pyrazinyl, or pyridyl, wherein each of these radicals may optionally be substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, benzyloxy; or more specifically wherein
- 20 (n) R^1 is phenyl optionally substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy; quinolinyl; a radical (c-4) wherein m is 2, optionally substituted with up to two radicals selected from C_{1-6} alkyl; benzimidazolyl optionally substituted with C_{1-6} alkyl; pyridyl optionally substituted with one or two radicals selected from hydroxy, halo, C_{1-6} alkyl, benzyloxy and C_{1-6} alkyloxy, pyrazinyl optionally substituted with up to three
- 25 radicals selected from C_{1-6} alkyl; or pyridyl substituted or optionally substituted as specified above in (a) – (i); or wherein
- (o) R^1 is phenyl optionally substituted with one or two radicals selected from the group consisting of halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy; or
- (p) R^1 is quinolinyl; or
- 30 (q) R^1 is a radical (c-4) wherein m is 2, optionally substituted with up to two radicals selected from C_{1-6} alkyl; or
- (r) R^1 is benzimidazolyl optionally substituted with C_{1-6} alkyl; pyridyl optionally substituted with one or two radicals selected from hydroxy, halo, C_{1-6} alkyl, benzyloxy and C_{1-6} alkyloxy; or
- 35 (s) R^1 is pyrazinyl optionally substituted with up to three radicals selected from C_{1-6} alkyl.

Preferred subgroups of compounds of formula (I) or any of the subgroups of compounds of formula (I) are those wherein G is a direct bond or methylene and R¹ is as specified above in (a) – (s). Further preferred are the compounds of formula (I) or any of the subgroups specified herein wherein G is a direct bond and R¹ is a radical (c-4), in particular wherein m is 2, optionally substituted with up to two radicals selected from C₁₋₆alkyl. Further preferred are the compounds of formula (I) or any of the subgroups specified herein wherein G is methylene and R¹ is as specified above in (a) – (s), but is other than a radical (c-4).

- 10 Other embodiments comprise those compounds of formula (I) or any of the subgroups of compounds of formula (I) specified herein, wherein R⁵ is hydrogen.

Further embodiments comprise those compounds of formula (I) or any of the subgroups of compounds of formula (I) specified herein, wherein

- 15 (a) Q is C₁₋₆alkyl optionally substituted with one or more substituents each independently selected from the group consisting of trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, C₁₋₄alkylthio, Ar²-oxy-, Ar²-thio-, Ar²(CH₂)_noxy, Ar²(CH₂)_nthio, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkyl-carbonyl, Ar²carbonyl, C₁₋₄alkoxycarbonyl, Ar²(CH₂)_ncarbonyl, aminocarbonyl-oxy, C₁₋₄alkylcarbonyloxy, Ar²carbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyloxy, aminosulfonyl, mono- or di(C₁₋₄alkyl)amino-sulfonyl or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₆alkyl; or in particular wherein
- 20 (b) Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from the group consisting of trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, C₁₋₄alkylthio, Ar²-oxy-, Ar²(CH₂)_noxy, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, C₁₋₄alkylcarbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxy-carbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₆alkyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from the group consisting of amino, mono- and diC₁₋₄alkylamino and Ar²-C₁₋₄alkylamino
- 25
- 30
- 35

and the other substituent is selected from the group consisting of carboxyl, C₁₋₆alkyloxycarbonyl and Ar²-C₁₋₄alkyloxycarbonyl; or more in particular wherein

- (c) Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, Ar²-oxy-, Ar²(CH₂)_noxy, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₆alkyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl;
- (d) Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, Ar²carbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from pyrrolidinyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₆alkyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from amino, mono- and diC₁₋₄alkylamino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl; or preferably wherein
- (e) Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from pyrrolidinyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, pyridyl and tetrahydropyridyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from amino, mono- and diC₁₋₄alkylamino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl; or more preferably wherein
- (f) Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from Ar², hydroxy, hydroxycarbonyl, aminocarbonyl,

- C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl, pyridyl and tetrahydropyridyl; or
 5 Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl; or more preferably wherein
- (g) Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl; or Q is
 10 C₁₋₆alkyl substituted with two substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl; or
- 15 (h) Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl; or wherein
- 20 (i) Q is C₁₋₆alkyl optionally substituted with one substituent selected from aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl, and optionally with a second substituent which is hydroxy; or
 25 Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl;
- (j) Q is C₁₋₆alkyl optionally substituted with one substituent selected from aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or
 30 di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl, and optionally with a second substituent which is hydroxy or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl; or wherein
- 35 (k) Q is C₁₋₆alkyl optionally substituted with one substituent selected from aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and

tetrahydropyridyl, and optionally with a second substituent which is hydroxy; or wherein

- (l) Q is C₁₋₆alkyl optionally substituted with aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl; or wherein
- (m) Q is C₁₋₆alkyl substituted with aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl or tetrahydropyridyl.

In particular, Ar¹ is phenyl or phenyl substituted with 1, 2, 3 substituents or with 1, 2 substituents selected from those mentioned in the definition of the compounds of formula (I) or of any subgroup thereof.

Further in particular, Ar² is phenyl or phenyl substituted with 1, 2, 3 substituents or with 1, 2 substituents selected from the group consisting of those mentioned in the definition of the compounds of formula (I) or of any subgroup thereof.

In the group of compounds of formula (I) or in any of the subgroups of compounds of formula (I):

- (a) Ar¹ preferably is phenyl or phenyl substituted with up to 3 substituents, or with up to 2 substituents, or with one substituent, selected from halo, hydroxy, C₁₋₆alkyl, hydroxyc₁₋₆alkyl, trifluormethyl, and C₁₋₆alkyloxy;
- (b) Ar¹ more preferably is phenyl or phenyl substituted with up to 3 substituents, or with up to 2 substituents, or with one substituent, selected from halo, hydroxy, C₁₋₆alkyl and C₁₋₆alkyloxy;
- (c) Ar¹ more preferably is phenyl or phenyl substituted with up to 3 substituents, or with up to 2 substituents, or with one substituent, selected from halo and C₁₋₆alkyl.

Further particular subgroups of the compounds of formula (I) are those compounds of formula (I), or any subgroup of compounds of formula (I) specified herein, wherein Ar² is as defined for Ar¹.

Further particular subgroups of the compounds of formula (I) are those compounds of formula (I), or any subgroup of compounds of formula (I) specified herein, wherein one of R^{2a} and R^{3a} is C₁₋₆alkyl and the other one of R^{2a} and R^{3a} is hydrogen; in case R^{2a} is different from hydrogen then R^{2b} is C₁₋₆alkyl, and R^{3b} is hydrogen;

in case R^{3a} is different from hydrogen then R^{3b} is C_{1-6} alkyl, and R^{2b} is hydrogen.

Particular subgroups of compounds comprises the group of compounds or formula (I) or any subgroup specified herein, wherein R^{2a} , R^{2b} , R^{3a} are hydrogen and R^{3b} is


5 C_{1-6} alkyl.

Other interesting compounds are those compounds of formula (I) including any subgroups of the compounds of formula (I) wherein t is 2.

10 Preferred compounds are those compounds listed in tables 1 through 3, more in particular the compound numbers 1 to 10 and 17 to 31.

The compounds of formula (I) or any of the subgroups thereof can be prepared as in the following reaction schemes.

15



In these schemes Q , G , t , R^1 , R^{2a} , R^{2b} , R^{3a} , R^{3b} , R^5 have the meanings defined above for the compounds of formula (I) or of any of the subgroups thereof. W is an

20 appropriate leaving group, preferably it is chloro or bromo. The reactions of these schemes can be typically conducted in a suitable solvent such as an ether, e.g. THF, a halogenated hydrocarbon, e.g. dichloromethane, $CHCl_3$, toluene, a polar aprotic solvent such as DMF, DMSO, DMA and the like. A base may be added to pick up the acid that is liberated during the reaction. If desired, certain catalysts such as iodide salts (e.g. KI)

25 may be added.

Compounds of formula (I) may be converted into each other following art-known functional group transformation reactions, comprising those described hereinafter.


Compounds of formula (I) wherein R^5 is hydrogen may be converted to corresponding compounds of formula (I) wherein is other than hydrogen by an N-alkylation reaction which may be conducted under similar conditions as described above for the conversion of (II) or of (IV) to (I).

5

A number of the intermediates used to prepare the compounds of formula (I) are known compounds or are analogs of known compounds, which can be prepared following modifications of art-known methodologies readily accessible to the skilled person. A number of preparations of intermediates are given hereafter in somewhat more detail.

10

The intermediates of formula (II) and (IV) can be prepared as outlined in the following reaction schemes.



15

In a first step, a diaminobenzene (VI) is cyclized with urea, preferably in a suitable solvent, e.g. xylene, to yield a benzimidazolone (VII). The latter is converted to a benzimidazole derivative (VIII) wherein W is a leaving group as specified above, in particular by reaction of (VII) with a suitable halogenating agent, for example POCl₃.

- 5 The resulting intermediate (VIII) is reacted with the cyclic amine derivative (IX) in an N-alkylation reaction to obtain (VIII-a) which is converted with R¹-G-W to intermediate (X). The group PG in (IX) and (X) represents a suitable N-protecting group, e.g. an alkylloxycarbonyl group such as an ethyloxycarbonyl group, which can be readily removed, e.g. by a base to yield intermediates (II).

10

Intermediate (VIII) can be similarly reacted with a cyclic amine (XII) in an N-alkylation reaction to yield intermediate (IV). The above-mentioned N-alkylations are conducted in a suitable solvent and, if desired, in the presence of a base.

- 15 The compounds of formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth
20 alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g.
25 ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

- Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical
30 methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.

- The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another
35 following art-known resolution procedures. The racemic compounds of formula (I) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of

separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the
5 reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

In a further aspect, the present invention concerns a pharmaceutical composition
10 comprising a therapeutically effective amount of a compound of formula (I) as specified herein, or a compound of any of the subgroups of compounds of formula (I) as specified herein, and a pharmaceutically acceptable carrier. A therapeutically effective amount in this context is an amount sufficient to prophylactically act against, to stabilize or to reduce viral infection, and in particular RSV viral infection, in
15 infected subjects or subjects being at risk of being infected. In still a further aspect, this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound of formula (I), as specified herein, or of a compound of any of the subgroups of compounds of formula (I) as specified
20 herein.

Therefore, the compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for
25 systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form or metal complex, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical
30 compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions
35 and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are

obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.

The compounds of the present invention may also be administered via oral inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder, a solution being preferred. Any system developed for the delivery of solutions, suspensions or dry powders via oral inhalation or insufflation are suitable for the administration of the present compounds.

Thus, the present invention also provides a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (I) and a pharmaceutically acceptable carrier. Preferably, the compounds of the present invention are administered via inhalation of a solution in nebulized or aerosolized doses.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

The compounds of formula (I) show antiviral properties. Viral infections treatable using the compounds and methods of the present invention include those infections

brought on by ortho- and paramyxoviruses and in particular by human and bovine respiratory syncytial virus (RSV). A number of the compounds of this invention moreover are active against mutated strains of RSV. Additionally, many of the compounds of this invention show a favorable pharmacokinetic profile and have
5 attractive properties in terms of bioavailability, including an acceptable half-life, AUC and peak values and lacking unfavourable phenomena such as insufficient quick onset and tissue retention.

The *in vitro* antiviral activity against RSV of the present compounds was tested in a test
10 as described in the experimental part of the description, and may also be demonstrated in a virus yield reduction assay. The *in vivo* antiviral activity against RSV of the present compounds may be demonstrated in a test model using cotton rats as described in Wyde et al. (Antiviral Research (1998), 38, 31-42).

15 Due to their antiviral properties, particularly their anti-RSV properties, the compounds of formula (I) or any subgroup thereof, their prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms, are useful in the treatment of individuals experiencing a viral infection, particularly a RSV infection, and for the prophylaxis of these infections. In general, the compounds of the present
20 invention may be useful in the treatment of warm-blooded animals infected with viruses, in particular the respiratory syncytial virus.

The compounds of the present invention or any subgroup thereof may therefore be used as medicines. Said use as a medicine or method of treatment comprises the systemic
25 administration to viral infected subjects or to subjects susceptible to viral infections of an amount effective to combat the conditions associated with the viral infection, in particular the RSV infection.

The present invention also relates to the use of the present compounds or any subgroup thereof in the manufacture of a medicament for the treatment or the prevention of viral
30 infections, particularly RSV infection.

The present invention furthermore relates to a method of treating a warm-blooded animal infected by a virus, or being at risk of infection by a virus, in particular by RSV,
35 said method comprising the administration of an anti-virally effective amount of a compound of formula (I), as specified herein, or of a compound of any of the subgroups of compounds of formula (I), as specified herein.

In general it is contemplated that an antiviral effective daily amount would be from 0.01 mg/kg to 500 mg/kg body weight, more preferably from 0.1 mg/kg to 50 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.

The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.

Also, the combination of another antiviral agent and a compound of formula (I) can be used as a medicine. Thus, the present invention also relates to a product containing (a) a compound of formula (I), and (b) another antiviral compound, as a combined preparation for simultaneous, separate or sequential use in antiviral treatment. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers. For instance, the compounds of the present invention may be combined with interferon-beta or tumor necrosis factor-alpha in order to treat or prevent RSV infections.

Examples

The following examples are intended to illustrate the present invention and not to limit it thereto. The terms "compound 1", "compound 4" etc used in these examples refer to the same compounds in the tables.

The compounds were analyzed by LC/MS using the following equipment:


LCT: electrospray ionisation in positive mode, scanning mode from 100 to 900 amu; Xterra MS C18 (Waters, Milford, MA) 5 μ m, 3.9 x 150 mm); flow rate 1 ml/min. Two mobile phases (mobile phase A: 85% 6.5mM ammonium acetate + 15% acetonitrile; mobile phase B: 20% 6.5 mM ammonium acetate + 80% acetonitrile) were employed to run a gradient from 100 % A for 3 min to 100% B in 5 min., 100% B for 6 min to 100 % A in 3 min, and equilibrate again with 100 % A for 3

min).

ZQ: electrospray ionisation in both positive and negative (pulsed) mode scanning from 100 to 1000 amu; Xterra RP C18 (Waters, Milford, MA) 5 μ m, 3.9 x 150 mm);
 5 flow rate 1 ml/min. Two mobile phases (mobile phase A: 85% 6.5mM ammonium acetate + 15% acetonitrile; mobile phase B: 20% 6.5 mM ammonium acetate + 80% acetonitrile) were employed to run a gradient condition from 100 % A for 3 min to 100% B in 5 min., 100% B for 6 min to 100 % A in 3 min, and equilibrate again with 100 % A for 3 min).

Example 1: Preparation of dimethylbenzimidazole intermediates

Scheme A-1




- a) The mixture of **a-1** (0.06 mol) and POCl₃ (100 ml) was heated at 100°C and HCl 12N (2.5 ml) was added drop wise very carefully. The reaction was then stirred during 12 hours at 120°C and allowed to cool down to room temperature. The solvent was evaporated under reduced pressure and a 10% solution of potassium carbonate in water was added to the residue. The resulting precipitate was filtered off, rinsed with water and dried, yielding 10 g of **a-2** (93%, melting point = 152°C).

- b) **a-2** (0.022 mol) and **a-3** (0.088 mol) were stirred at 130°C during 12 hours. The reaction was then allowed to cool down to room temperature, the residue was taken up in acetone and the precipitate was filtered off. The acetone solution was concentrated under reduced pressure. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/MeOH/NH₄OH 95/5/0.1). The pure fractions were collected and the solvent was evaporated, yielding 5 g of **a-4** (72%).
- c) A mixture of **a-4** (0.0158 mol), **a-5** (0.019 mol) and potassium carbonate (0.0553 mol) in dimethylformamide (100ml) was stirred at 70°C for 24 hours. The solvent was evaporated until dryness. The residue was taken up in CH₂Cl₂/CH₃OH (90/10). The organic layer was washed with a 10% solution of K₂CO₃ in water, dried (over MgSO₄), filtered and the solvent was evaporated under reduced pressure. The residue was taken up in 2-propanone. The precipitate was filtered off, washed with H₂O and dried, yielding 5g of **a-6** and **a-7** (50/50 mixture, 73%).
- d) A mixture of **a-6** and **a-7** (0.0103 mol) in a 48% solution of HBr in water (50ml) was stirred at 60°C during 12 hours. The solvent was evaporated until dryness. The residue was taken up in CH₂Cl₂/CH₃OH (90/10). 10% solution of K₂CO₃ in water was added. The aqueous layer was saturated with K₂CO₃ (powder). The organic layer was separated, dried (over MgSO₄), filtered, and the solvent was evaporated until dryness, yielding 3.7g of **a-8** and **a-9** (100%). This product was used directly in the next reaction step.

Example 2: Preparation of dimethylbenzimidazole end products

Scheme A-2:



Variant 1:

A mixture of **a-8** (0.0002 mol), **a-9** (0.0002 mol), 2-bromo-ethanol (0.0006 mol) and

triethylamine (0.0011 mol) in acetonitrile (10ml) was stirred at 30°C for 12 hours. The solvent was evaporated until dryness. The residue was taken up in CH₂Cl₂. The organic layer was washed with H₂O, dried (over MgSO₄), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 85/15/1; 10µm). Two fractions were collected and the solvent was evaporated, yielding: 0.028g fraction 1 (12.4%) and 0.05g fraction 2 (22%). Fraction 1 was crystallized from 2-propanone/diisopropylether. The precipitate was filtered off and dried, yielding 0.015g of 2-{2-[1-(2-hydroxy-ethyl)-piperidin-4-ylamino]-5,7-dimethyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol (6.6%, melting point: 143°C). Fraction 2 was crystallized from 2-propanone/diisopropylether. The precipitate was filtered off and dried, yielding 0.03g of 2-{2-[1-(2-hydroxy-ethyl)-piperidin-4-ylamino]-4,6-dimethyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol (compound 2, 13%, melting point: 177°C).

Variant 2:

A mixture of **a-8** (0.0008 mol), **a-9** (0.0008 mol), 3-chloro-propane-sulfonamide (0.0019 mol) and triethylamine (0.0024 mol) in dimethylformamide (50ml) was stirred at 70°C for 12 hours, then poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (over MgSO₄), filtered and the solvent was evaporated until dryness. The residue (1g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 90/10/0.5; 15-40µm). The pure fractions were collected and the solvent was evaporated, yielding 0.12g of 3-{4-[1-(3-hydroxy-6-methyl-pyridin-2-ylmethyl)-4,6-dimethyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propane-1-sulfonic acid amide (compound 1, 15%, melting point: 180°C).


Variant 3

LiAlH₄ (0.0002 mol) was added at 5°C to a mixture of 3-{4-[1-(3-Hydroxy-6-methyl-pyridin-2-ylmethyl)-4,6-dimethyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propionic acid ethyl ester (0.00009 mol; melting point: 172°C; prepared according to the procedure described in variant 2) in tetrahydrofuran (10ml) under N₂ flow. The mixture was stirred at 5°C for 1 hour, then at room temperature for 3 hours. A minimum of H₂O and ethylacetate were added. The organic layer was separated, dried (over MgSO₄), filtered and the solvent was evaporated until dryness. The residue was crystallized from 2-propanone/CH₃CN/diisopropylether. The precipitate was filtered off and dried, yielding 0.026g of 2-{2-[1-(3-hydroxy-propyl)-piperidin-4-ylamino]-4,6-dimethyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol (compound 4, 68%, melting point: 209°C).

Variant 4

- A mixture of 3-{4-[1-(3-Hydroxy-6-methyl-pyridin-2-ylmethyl)-4,6-dimethyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propionic acid ethyl ester (0.0065 mol) in methanol/NH₃ 7N (15ml) was stirred in a sealed vessel at 70°C for 12 hours. The solvent was evaporated until dryness. The residue (0.3g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 85/14/1; 5µm). The pure fractions were collected and the solvent was evaporated. The residue (0.09g, 32%) was crystallized from diisopropylether. The precipitate was filtered off and dried, yielding 0.086g of 3-{4-[1-(3-hydroxy-6-methyl-pyridin-2-ylmethyl)-4,6-dimethyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propionamide (compound 5, 30%, melting point: 212°C).


Table 1 – compounds prepared according to scheme A-2




Comp. No.	-R	Activity	Mass Spectroscopy	Melting point	variant
1		8.7	MH ⁺ = 487	180°C	2
2		8.5	MH ⁺ = 410	177°C	1
3		8.5	MH ⁺ = 473	242°C	2
4		8.1	MH ⁺ = 424	209°C	3
5			MH ⁺ = 437	212°C	4
6		7.8	MH ⁺ = 501	179°C	2
7		7.6	MH ⁺ = 451	186°C	4
8		7.6	MH ⁺ = 438	206°C	3

Comp. No.	-R	Activity	Mass Spectroscopy	Melting point	variant
9		7.4	MH ⁺ = 451	206°C	4
10		7.1	MH ⁺ = 466	172°C	2
11		6.8	MH ⁺ = 423	226°C	4
12		6.8	MH ⁺ = 462	>260°C	2
13		6.5	MH ⁺ = 452	186°C	1
14		6.5	MH ⁺ = 471	161°C	2


Table 2 – Further compounds prepared according to scheme A-2



Comp. No.	R	Activity	Mass Spectroscopy	Melting point	variant
15		6.4	MH ⁺ = 410	143°C	1
16		5.8	MH ⁺ = 452	186°C	2

Example 3: Preparation of methylbenzimidazole intermediates**5 Scheme B-1**

-30-




- a) The preparation of this intermediate **b-3** is analogous to the preparation of intermediate **a-4**.
- b) The preparation of these intermediates **b-5** and **b-6** is analogous to the preparation of intermediates **a-6** and **a-7**.
- c) The preparation of these intermediates **b-7** and **b-8** is analogous to the preparation of intermediates **a-8** and **a-8**. Further to that, **b-7** has been isolated pure after crystallization with diisopropylether (melting point: $> 260^\circ\text{C}$).

Example 4: Preparation of methylbenzimidazole intermediates end products

Scheme B-2

Variant 1




- a) A mixture of **b-7** (0.0056 mol), **b-9** (0.0113 mol) and K_2CO_3 (0.0171 mol) in CH_3CN (30ml) was stirred and refluxed for 6 hours. The solvent was evaporated.

The residue was taken up in CH_2Cl_2 and washed with a saturated solution of NaCl in water. The organic layer was separated, dried (over MgSO_4), filtered and the solvent was evaporated. The residue (2.4g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 95/5/0.2; 15-40 μm). The pure fractions were collected and the solvent was evaporated, yielding 1g of intermediate **b-10** (32%).


- b) A saturated solution of HCl in 2-propanol (1.5ml) was added at room temperature to a mixture of **b-10** (0.0013 mol) in 2-propanol (15ml). The mixture was stirred at 60°C for 12 hours, and then cooled to room temperature. The precipitate was filtered, washed with 2-propanol, then with diethyl ether and dried, yielding 0.79g. This fraction was crystallized from 2-propanol. The precipitate was filtered, washed with diethyl ether and dried, yielding 0.11g of **b-11** (14%).
- c) A mixture of **b-11** (0.0011 mol) in a 3N solution of HCl in water (5ml) was stirred and refluxed for 6 hours, then cooled to room temperature and the solvent was evaporated. The residue (0.4g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 70/30/3; 15-40 μm). Two fractions were collected and the solvent was evaporated. Yielding: 0.111g. This fraction was crystallized from ethanol. The precipitate was filtered off and dried, yielding 0.03g of **b-12** (compound 23, 5%, melting point: 195°C).

Variant 2:




3-{4-[1-(3-hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propane-1-sulfonic acid amide (compound 19, melting point: 250°C) was prepared analogous to the procedure described in variant 2, scheme A-2.

Variant 3:




-32-



- a) A mixture of **b-14** (0.0236 mol), benzyl bromide (Bz-Br, 0.026 mol) and K_2CO_3 (0.0354 mol) in a mixture of CH_3CN (50ml), dimethylformamide (50ml) and tetrahydrofuran (100ml) was stirred at 60°C for 24 hours. The solvent was evaporated until dryness. The residue was taken up in H_2O . The precipitate was filtered, washed with H_2O and extracted with diethyl ether. The organic layer was separated, dried (over $MgSO_4$), filtered and the solvent was evaporated until dryness. The residue (12g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 98/2/0.1; 15-40 μm). Three fractions were collected and the solvent was evaporated, yielding 5g of **b-15** (41.3%).
- b) A mixture of **b-15** (0.0095 mol) and KOH (0.0095 mol) in 2-propanol (60ml) was stirred and refluxed for 4 hours. The solvent was evaporated until dryness. The residue was taken up in CH_2Cl_2 . The organic layer was washed with H_2O , dried (over $MgSO_4$), filtered and the solvent was evaporated until dryness, yielding 5g of **b-16** (>100%, melting point: 182°C). The product was used directly in the next reaction step.
- c) A mixture of **b-16** (0.0307 mol), ethyl chloro-acetate (0.037 mol) and K_2CO_3 (0.046 mol) in CH_3CN (150ml) was stirred at 60°C for 12 hours. The solvent was evaporated until dryness. The residue was taken up in CH_2Cl_2 . The organic layer was washed with H_2O , dried (over $MgSO_4$), filtered and the solvent was evaporated until dryness. The residue was crystallized from 2-propanone/ CH_3CN . The precipitate was filtered off and dried, yielding 14.5g of **b-17** (89.5%, melting point: 116°C).

- d) LiAlH_4 (0.047 mol) was added portion wise at 5°C to a mixture of **b-17** (0.023 mol) in tetrahydrofuran (250ml) under N_2 flow. The mixture was stirred at 5°C for 2 hours. H_2O was added. The mixture was extracted with ethylacetate and filtered over celite. The organic layer was separated, dried (over MgSO_4), filtered and the solvent was evaporated until dryness, yielding 8g of **b-18** (71.6%, melting point: 159°C).
- e) A mixture of **b-18** (0.0004 mol) and Pd/C (0.1g) in CH_3OH (20ml) was hydrogenated at 40°C for 3 hours under a 5 bar pressure, then cooled and filtered over celite. The filtrate was evaporated until dryness, yielding 0.16g (100%). This fraction was crystallized from 2-propanone/diisopropylether. The precipitate was filtered off and dried, yielding 0.07g of **b-19** (compound 22, 43%, melting point: 258°C).

Variant 4:



- 15 a) SOCl_2 (0.0214 mol) was added drop wise to a solution of **b-19** in CH_2Cl_2 at 0°C . The reaction was stirred at room temperature for 5 hours. The precipitate was filtered off, rinsed with diisopropylether and dried, yielding **b-20** (100%). The crude compound was used in the next reaction step.
- 20 b) A mixture of **b-20** (0.0011 mol), K_2CO_3 (0.0038 mol) and pyrrolidine (0.0013 mol) in CH_3CN (10ml) was stirred at 70°C for 12 hours. H_2O was added. The mixture was extracted with CH_2Cl_2 . The organic layer was separated, dried (over MgSO_4), filtered and the solvent was evaporated. The residue (0.27g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 88/11/1; $10\mu\text{m}$). The pure fractions were collected and the solvent was evaporated.
- 25 The residue (0.14g) was crystallized from $\text{CH}_3\text{CN}/2$ -propanone. The precipitate was filtered off and dried, yielding 0.105g of 6-Methyl-2-{4-methyl-2-[1-(2-pyrrolidin-

1-yl-ethyl)-piperidin-4-ylamino]-benzoimidazol-1-ylmethyl}-pyridin-3-ol
(compound 18, 28%, melting point: 225°C).

Variant 5

- 5 a) 3-{4-[1-(3-Hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propionic acid ethyl ester (melting point: 226°C) was prepared analogous to the procedure described for the preparation of **b-19**.
b) 3-{4-[1-(3-Hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propionamide (compound 27, melting point: 258°C) was prepared according to the procedure described in variant 4, scheme A-2.

10 Variant 6

- a) A mixture of **b-18** (0.002 mol), phenyl-acetic acid (0.0024 mol), DCC (0.0029 mol) and DMAP (0.0029 mol) in THF (50ml) was stirred at room temperature for 12 hours. H₂O was added. The mixture was extracted with ethylacetate and filtered. The organic layer was separated, dried (over MgSO₄), filtered and the solvent was
15 evaporated until dryness. The residue (1.5g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.1; 15-35µm). The pure fractions were collected and the solvent was evaporated. The residue (1.2g, 96%) was crystallized from diisopropylether. The precipitate was filtered off and dried, yielding 0.8g of phenylacetic acid-2-{4-[1-(3-benzyloxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-ethyl ester
20 (64%, melting point: 105°C).
b) Phenyl-acetic acid 2-{4-[1-(3-hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-ethyl ester (compound 24, melting point: 207°C) was prepared analogous to the procedure described for **b-19**.

25 Variant 7:

- a) A mixture of 3-{4-[1-(3-Hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propionic acid ethyl ester (0.0009 mol) in a 3N solution of HCl in water (5ml) was stirred and refluxed for 18 hours and then cooled to room temperature. The precipitate was filtered, washed with diethyl
30 ether and dried, yielding 0.18g of 3-{4-[1-(3-hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-propionic acid hydrochloride salt (compound 33, 31%, melting point: 245°C).

Variant 8:

- a) 1-{4-[1-(3-Hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-

ylamino]-piperidin-1-yl}-3-methyl-butan-2-one was prepared analogous to the procedure described for **b-19**.

- b) NaBH₄ (0.0003 mol) was added portion wise to a solution of 1-{4-[1-(3-Hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-3-methyl-butan-2-one (0.0002 mol) in tetrahydrofuran (2ml) and CH₃OH (2ml) at 5°C. The mixture was stirred at room temperature for 4 hours. 10% solution of K₂CO₃ in water was added. The mixture was extracted with CH₂Cl₂. The organic layer was washed with H₂O, dried (over MgSO₄), filtered and the solvent was evaporated. The residue (0.08g) was dissolved in CH₂Cl₂/CH₃OH and crystallized from diisopropylether. The precipitate was filtered, washed with diisopropylether and dried, yielding 0.049g of 2-{2-[1-(2-hydroxy-3-methyl-butyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol (compound 35, 48%, melting point: 230°C).

Variant 9:

- a) Chlorosulfonyl isocyanate (0.0021 mol) was added at -30°C to a mixture of **b-18** (0.0009 mol) in ethylacetate (15ml) under N₂ flow. The mixture was stirred at -30°C for 1 hour, then brought to 0°C. H₂O (0.5ml), HCl 12N (0.5ml) then CH₃OH (1ml) was added. The mixture was stirred at 40°C for 1 hour, then cooled, basified with K₂CO₃ and extracted with ethylacetate. The organic layer was separated, dried (over MgSO₄), filtered and the solvent was evaporated until dryness, yielding 0.46g of carbamic acid 2-{4-[1-(3-benzyloxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-ethyl ester (94%).
- b) Carbamic acid 2-{4-[1-(3-hydroxy-6-methyl-pyridin-2-ylmethyl)-4-methyl-1H-benzoimidazol-2-ylamino]-piperidin-1-yl}-ethyl ester (compound 37, melting point: 222°C) has been prepared analogous to the procedure described for **b-19**.


Variant 10:

- A mixture of **b-7** (0.0014 mol), glycidyl 4-methoxyphenyl ether (0.0021 mol) in ethanol (10ml) was stirred and refluxed for 4 hours, then cooled to room temperature and the solvent was evaporated. The residue (0.75g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 90/10; 15-40µm). The pure fractions were collected and the solvent was evaporated, yielding 0.101g of 2-(2-{1-[2-hydroxy-3-(4-methoxy-phenoxy)-propyl]-piperidin-4-ylamino}-4-methyl-benzoimidazol-1-ylmethyl)-6-methyl-pyridin-3-ol (compound 41, 13%, melting point: 227°C).

















Variant 11:














- Formaldehyde 37% in water (0.0017 mol) and NaBH₃CN (0.001 mol) were added at room temperature to a mixture of **b-7** (0.0008 mol) in CH₃CN (1ml). Acetic acid (0.3ml) was added drop wise. The mixture was stirred at room temperature overnight. The solvent was evaporated until dryness. Ethanol (3ml) and a saturated solution of
- 5 HCl in 2-propanol (1ml) were added. The mixture was stirred at 80°C for 2 hours, basified with K₂CO₃ 10% in water and extracted with CH₂Cl₂. The organic layer was separated, dried (over MgSO₄), filtered and the solvent was evaporated. The residue (0.21g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 90/10/0.1 to 80/20/3; 35-70μm). The pure fractions were collected and
- 10 the solvent was evaporated until dryness, yielding 0.1g of 6-methyl-2-[4-methyl-2-(1-methyl-piperidin-4-ylamino)-benzoimidazol-1-ylmethyl]-pyridin-3-ol, Compound 34 (32%, melting point: 210°C).



Table 3 – compounds prepared according to Scheme B-2



Comp. No.	R	Activity	Mass Spectroscopy	Melting point	Variant	Salt
17		8.7	MH ⁺ = 452	210°C	1	HCl
18		8.0	MH ⁺ = 449	225°C	4	
19		7.9	MH ⁺ = 473	250°C	2	
20		7.9	MH ⁺ = 426	240°C	2	
21		7.8	MH ⁺ = 461	—	4	
22		7.7	MH ⁺ = 396	258°C	3	
23		7.6	MH ⁺ = 437	195°C	1	HCl

Comp. No.	R	Activity	Mass Spectroscopy	Melting point	Variant	Salt
24		7.5	MH ⁺ = 514	207°C	6	
25		7.5	MH ⁺ = 477		4	
26		7.4	MH ⁺ = 447		4	
27		7.3	MH ⁺ = 423	258°C	5	
28		7.3	MH ⁺ = 487	217°C	2	
29		7.2	MH ⁺ = 424	>260°C	3	
30		5.2	MH ⁺ = 410	205°C	7	HCl
31		7.1	MH ⁺ = 451	220°C	2	
32		6.8	MH ⁺ = 452	226°C	2	
33		6.8	MH ⁺ = 424	245°C	7	HCl
34		6.8	MH ⁺ = 466	210°C	11	
35		6.8	MH ⁺ = 438	230°C	8	
36		6.8	MH ⁺ = 565	>260°C	2	
37		6.8	MH ⁺ = 439	222°C	9	
38		6.8	MH ⁺ = 446		4	
39		6.6	MH ⁺ = 472	229°C	8	

Comp. No.	R	Activity	Mass Spectroscopy	Melting point	Variant	Salt
40		6.5	MH ⁺ = 450	230°C	3	
41		6.5	MH ⁺ = 532	227°C	10	
42		6.5	MH ⁺ = 520	230°C	10	
43		6.5	MH ⁺ = 502	228°C	10	
44		6.4	MH ⁺ = 409	254°C	5	
45		6.4	MH ⁺ = 486	158°C	10	
46		6.4	MH ⁺ = 447		4	
47		6.3	MH ⁺ = 558	228°C	2	
48		6.2	MH ⁺ = 422	230°C	3	
49		6.1	MH ⁺ = 436		3	
50		6.1	MH ⁺ = 452	255°C	8	
51		5.9	MH ⁺ = 468	105°C	6	
52		5.8	MH ⁺ = 558	196°C	2	

Comp. No.	R	Activity	Mass Spectroscopy	Melting point	Variant	Salt
53		5.7	MH ⁺ = 438	159°C	3	
54		5.7	MH ⁺ = 464	>260°C	10	

Example 5: In vitro screening for activity against Respiratory Syncytial Virus.


The percent protection against cytopathology caused by viruses (antiviral activity or EC₅₀) achieved by tested compounds and their cytotoxicity (CC₅₀) are both calculated from dose-response curves. The selectivity of the antiviral effect is represented by the selectivity index (SI), calculated by dividing the CC₅₀ (cytotoxic dose for 50% of the cells) by the EC₅₀ (antiviral activity for 50 % of the cells). The tables in the above experimental part list the category to which each of the prepared compounds belong : Compounds belonging to activity category "A" have an pEC₅₀ (-log of EC₅₀ when expressed in molar units) equal to or more than 7. Compounds belonging to activity category "B" have a pEC₅₀ value between 6 and 7. Compounds belonging to activity category "C" have a pEC₅₀ value equal to or below 6.

Automated tetrazolium-based colorimetric assays were used for determination of EC₅₀ and CC₅₀ of test compounds. Flat-bottom, 96-well plastic microtiter trays were filled with 180 µl of Eagle's Basal Medium, supplemented with 5 % FCS (0% for FLU) and 20 mM Hepes buffer. Subsequently, stock solutions (7.8 x final test concentration) of compounds were added in 45 µl volumes to a series of triplicate wells so as to allow simultaneous evaluation of their effects on virus- and mock-infected cells. Five five-fold dilutions were made directly in the microtiter trays using a robot system. Untreated virus controls, and HeLa cell controls were included in each test. Approximately 100 TCID₅₀ of Respiratory Syncytial Virus was added to two of the three rows in a volume of 50 µl. The same volume of medium was added to the third row to measure the cytotoxicity of the compounds at the same concentrations as those used to measure the antiviral activity. After two hours of incubation, a suspension (4 x 10⁵ cells/ml) of HeLa cells was added to all wells in a volume of 50µl. The cultures were incubated at 37°C in a 5% CO₂ atmosphere. Seven days after infection the cytotoxicity and the antiviral activity was examined spectrophotometrically. To each well of the microtiter tray, 25 µl of a solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added. The trays were further incubated at 37°C for 2 hours, after which the medium was removed from each cup. Solubilization of the formazan crystals was

achieved by adding 100 μ l 2-propanol. Complete dissolution of the formazan crystals were obtained after the trays have been placed on a plate shaker for 10 min. Finally, the absorbances were read in an eight-channel computer-controlled photometer (Multiskan MCC, Flow Laboratories) at two wavelengths (540 and 690 nm). The absorbance
5 measured at 690 nm was automatically subtracted from the absorbance at 540 nm, so as to eliminate the effects of non-specific absorption.

Claims

1. A compound of formula (I)











5 a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein

Q is C₁₋₆alkyl optionally substituted with one or more substituents each independently selected from the group consisting of trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, C₁₋₄alkylthio, Ar²-oxy-, Ar²-thio-, Ar²(CH₂)_noxy, Ar²(CH₂)_nthio, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, Ar²carbonyl, C₁₋₄alkoxycarbonyl, Ar²(CH₂)_ncarbonyl, aminocarbonyloxy, C₁₋₄alkylcarbonyloxy, Ar²carbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyloxy, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₆alkyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from the group consisting of amino, mono- and diC₁₋₄alkyl-amino and Ar²-C₁₋₄alkylamino and the other substituent is selected from the group consisting of carboxyl, C₁₋₆alkyloxycarbonyl, Ar²-C₁₋₄alkyloxycarbonyl, aminocarbonyl and aminosulfonyl;

G is a direct bond or C₁₋₁₀alkanediyl optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, C₁₋₆alkyloxy, Ar¹C₁₋₆alkyloxy, C₁₋₆alkylthio, Ar¹C₁₋₆alkylthio, HO(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-;

R¹ is Ar¹ or a monocyclic or bicyclic heterocycle being selected from piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro-furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl,

1*H*-imidazo[4,5-*b*]pyridinyl, 3*H*-imidazo[4,5-*b*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridyl or a radical of formula



;

wherein each of said monocyclic or bicyclic heterocycles may optionally be substituted

- 5 with 1 or where possible more, such as 2, 3, 4 or 5, substituents individually selected from the group of substituents consisting of halo, hydroxy, amino, cyano, carboxyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, Ar¹, Ar¹C₁₋₆alkyl, Ar¹C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)amino, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{4a}-, Ar¹-SO₂-NR^{4a}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{4a}R^{4b}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono- or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-;

each n independently is 1, 2, 3 or 4;

one of R^{2a} and R^{3a} is C₁₋₆alkyl and the other one of R^{2a} and R^{3a} is hydrogen;

- 15 in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C₁₋₆alkyl, and R^{3b} is hydrogen;

in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C₁₋₆alkyl, and R^{2b} is hydrogen; or

R^{3b} is C₁₋₆alkyl; and R^{3a}, R^{2a}, R^{2b} all are hydrogen; or

- 20 R^{2b} is C₁₋₆alkyl; and R^{3a}, R^{2a}, R^{3b} all are hydrogen;

R^{4a} and R^{4b} can be the same or can be different relative to one another, and are each independently hydrogen or C₁₋₆alkyl; or

R^{4a} and R^{4b} taken together may form a bivalent radical of formula $-(CH_2)_s-$;

R^5 is hydrogen or C_{1-6} alkyl;

m is 1 or 2;

p is 1 or 2;


5 s is 4 or 5;

t is 1, 2 or 3;

Ar^1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, polyhalo C_{1-6} alkyl, and C_{1-6} alkyloxy;


10 Ar^2 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from the group consisting of halo, hydroxy, amino, cyano, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, polyhalo C_{1-6} alkyl, amino C_{1-6} alkyl, C_{1-6} alkyloxy, amino-sulfonyl, aminocarbonyl, hydroxycarbonyl, C_{1-4} alkylcarbonyl, mono- or di(C_{1-4} alkyl)amino, mono- or di(C_{1-4} alkyl)aminocarbonyl, mono- or di(C_{1-4} alkyl)aminosulfonyl, mono- or di(C_{1-4} alkyl)amino C_{1-6} alkyl and C_{1-4} alkoxycarbonyl.

2. A compound as claimed in claim 1, wherein the compound has the formula



20 wherein Q , t , R^5 , G and R^1 are as claimed in claim 1; and
 R^{2a} is C_{1-6} alkyl;
 R^{2b} is hydrogen or C_{1-6} alkyl.


3. A compound as claimed in claim 1, wherein the compound has the formula



25 wherein Q , t , R^5 , G and R^1 are as claimed in claim 1; and
 R^{3a} is C_{1-6} alkyl;
 R^{3b} is hydrogen or C_{1-6} alkyl.

-44-

4. A compound as claimed in claim 1, wherein the compound has the formula



wherein Q, t, R⁵, G and R¹ are as claimed in claim 1; and
R^{3b} is C₁₋₆alkyl.

5

5. A compound as claimed in any of claims 1 to 4 wherein t is 2.
6. A compound as claimed in any of claims 1 to 5 wherein G is C₁₋₁₀alkanediyl.


- 10 7. A compound according to in any of claims 1 - 5, wherein G is methylene.

8. A compound according to any of claims 1 - 7, wherein R¹ is pyridyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of halo, hydroxy, amino, cyano, carboxyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, Ar¹, Ar¹C₁₋₆alkyl, Ar¹C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono-or di(C₁₋₆alkyl)amino, mono-or di(C₁₋₆alkyl)amino-C₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{4a}-, Ar¹-SO₂-NR^{4a}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{4a}R^{4b}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono-or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-.

9. A compound according to any of claims 1 - 7, wherein R¹ is pyridyl substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy and C₁₋₆alkyl.

25

10. A compound according to any of claims 1 - 7, wherein R¹ is Ar¹, quinolinyl, benzimidazolyl, a radical of formula




or pyrazinyl; wherein each of the radicals Ar¹, quinolinyl, benzimidazolyl, (c-4), or pyrazinyl may optionally be substituted with the substituents of said radicals as claimed in claim 1.

30

11. A compound according to any of claims 1 - 7, wherein R¹ is phenyl optionally substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy; quinolinyl; a radical (c-4) wherein m is 2,
5 optionally substituted with up to two radicals selected from C₁₋₆alkyl; benzimidazolyl optionally substituted with C₁₋₆alkyl; pyrazinyl optionally substituted with up to three radicals selected from C₁₋₆alkyl.
12. A compound according to any of claims 1 - 11, wherein R⁵ is hydrogen.
10
13. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, Ar²-oxy-,
15 Ar²(CH₂)_noxy, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxy-carbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxycarbonyl-(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycle selected from pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be
20 substituted with oxo or C₁₋₆alkyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is selected from amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl;
14. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl optionally substituted with one or two substituents each independently selected from aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy,
25 mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl; or Q is C₁₋₆alkyl substituted with two substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl.
30
15. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl optionally substituted with one substituent selected from aminocarbonyl, C₁₋₄alkoxy-carbonyl, aminocarbonyloxy, Ar²(CH₂)_ncarbonyloxy, mono- or di(C₁₋₄alkyl)-
35 aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl and tetrahydropyridyl, and optionally with a second substituent which is hydroxy or Q is C₁₋₆alkyl


substituted with two substituents wherein one substituent is amino and the other substituent is selected from carboxyl and C₁₋₆alkyloxycarbonyl.

16. A compound according to any of claims 1 - 12, wherein Q is C₁₋₆alkyl substituted with aminocarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyloxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, homopiperidinyl or tetrahydropyridyl.
17. A compound as claimed in any one of claims 1 to 16 for use as a medicine.
18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 16.
19. A process for preparing a pharmaceutical composition as claimed in claim 18, said process comprising intimately mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound as claimed in any one of claims 1 to 16.
20. The use of a compound as claimed in any of claims 1 to 16 for the manufacture of a medicament for inhibiting RSV replication.
21. A process for preparing a compound as claimed in any of claims 1 to 23, said process comprising
 - (a) reacting an intermediate of formula (II) with a reagent (III) as in the following reaction scheme:



- (b) reacting an intermediate of formula (IV) with a reagent (V) as in the following reaction scheme:

-47-



wherein Q, G, t, R¹, R^{2a}, R^{2b}, R^{3a}, R^{3b}, R⁵ are as claimed in any of claims 1 to 16;
 and optionally converting the thus obtained compounds of formula (I) into their
 pharmaceutically acceptable base-addition or acid addition salt form by treatment
 with a suitable base or acid and conversely treating the base-addition or acid
 addition salt form with an acid or a base to obtain the free form of the compound
 of formula (I).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/053606

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/14 A61K31/4184 C07D417/14 A61P11/00 A61P31/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/00612 A (JANSSENS FRANS EDUARD ;SOMMEN FRANCOIS MARIA (BE); ANDRIES KOENRAA) 4 January 2001 (2001-01-04) cited in the application examples 35-38; table 2	1-21
X	* example 51; table 3*	1
Y	WO 01/00615 A (JANSSENS FRANS EDUARD ;ANDRIES KOENRAAD JOZEF LODENWI (BE); JANSSE) 4 January 2001 (2001-01-04) cited in the application examples	1-21
Y	WO 01/00611 A (JANSSENS FRANS EDUARD ;SOMMEN FRANCOIS MARIA (BE); ANDRIES KOENRAA) 4 January 2001 (2001-01-04) cited in the application examples	1-21

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 April 2005

Date of mailing of the international search report

15/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/053606

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JANSSENS F ET AL: "NEW ANTIHISTAMINE N-HETEROCYCLIC 4-PIPERIDINAMINES. 2. SYNTHESIS AND ANTIHISTAMINIC ACTIVITY OF 1-(4-FLUOROPHENYL)METHYL-N- (4-PIPERIDINYL)-1H-BENZIMIDAZOL-2-AMINES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 28, no. 12, December 1985 (1985-12), pages 1934-1943, XP000881979 ISSN: 0022-2623 example 87	1-21
X	----- EP 0 005 318 A (JANSSEN PHARMACEUTICA NV) 14 November 1979 (1979-11-14) * see examples on pp 41, 44 *	1-21
A	----- WO 92/01687 A (JANSSEN PHARMACEUTICA NV) 6 February 1992 (1992-02-06) examples -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/053606

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0100612	A	04-01-2001	AT 258928 T 15-02-2004
			AU 778218 B2 25-11-2004
			AU 5816600 A 31-01-2001
			BG 106286 A 31-10-2002
			BR 0012047 A 12-03-2002
			CA 2376676 A1 04-01-2001
			CN 1358181 A 10-07-2002
			DE 60008112 D1 11-03-2004
			DE 60008112 T2 16-09-2004
			DK 1196409 T3 07-06-2004
			EA 5027 B1 28-10-2004
			EE 200100688 A 15-04-2003
			WO 0100612 A2 04-01-2001
			EP 1196409 A2 17-04-2002
			ES 2215683 T3 16-10-2004
			HR 20010935 A1 30-06-2003
			HU 0201869 A2 28-11-2002
			JP 2003503402 T 28-01-2003
			MX PA02000120 A 02-07-2002
			NO 20016369 A 20-02-2002
			NZ 515664 A 30-01-2004
			PL 352378 A1 25-08-2003
			PT 1196409 T 30-06-2004
			SI 1196409 T1 30-06-2004
			SK 19122001 A3 09-01-2003
			TR 200103806 T2 21-06-2002
			US 6747028 B1 08-06-2004
			ZA 200110479 A 20-03-2003
WO 0100615	A	04-01-2001	AT 259796 T 15-03-2004
			AU 774829 B2 08-07-2004
			AU 5222200 A 31-01-2001
			BG 106288 A 31-10-2002
			BR 0011997 A 05-03-2002
			CA 2376785 A1 04-01-2001
			CN 1358182 A 10-07-2002
			CZ 20014573 A3 15-05-2002
			DE 60008382 D1 25-03-2004
			DE 60008382 T2 02-12-2004
			DK 1196410 T3 28-06-2004
			EA 4746 B1 26-08-2004
			EE 200100694 A 17-02-2003
			WO 0100615 A1 04-01-2001
			EP 1196410 A1 17-04-2002
			EP 1400519 A1 24-03-2004
			ES 2215670 T3 16-10-2004
			HR 20010934 A1 30-06-2003
			HU 0201789 A2 28-11-2002
			JP 2003503403 T 28-01-2003
			MX PA02000117 A 02-07-2002
			NO 20016370 A 27-12-2001
			NZ 515392 A 26-03-2004
			PL 352385 A1 25-08-2003
			PT 1196410 T 30-07-2004
			SI 1196410 T1 31-08-2004
			SK 18952001 A3 06-11-2002
			TR 200103805 T2 21-06-2002
			ZA 200110473 A 20-03-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/053606

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0100611	A	04-01-2001	AT 276244 T	15-10-2004
			AU 5816700 A	31-01-2001
			BG 106287 A	31-10-2002
			BR 0012054 A	19-03-2002
			CA 2376781 A1	04-01-2001
			CN 1358180 A	10-07-2002
			CZ 20014574 A3	15-05-2002
			DE 60013836 D1	21-10-2004
			EA 4939 B1	28-10-2004
			EE 200100692 A	17-02-2003
			WO 0100611 A1	04-01-2001
			EP 1196408 A1	17-04-2002
			EP 1418175 A1	12-05-2004
			HR 20010933 A1	30-06-2003
			HU 0201723 A2	28-11-2002
			JP 2003503401 T	28-01-2003
			MX PA02000112 A	02-07-2002
			NO 20016368 A	28-02-2002
			NZ 515418 A	28-11-2003
			PL 362890 A1	02-11-2004
			SI 1196408 T1	28-02-2005
			SK 18942001 A3	08-10-2002
			TR 200103804 T2	21-05-2002
			ZA 200110478 A	20-03-2003
EP 0005318	A	14-11-1979	US 4219559 A	26-08-1980
			AT 373887 B	27-02-1984
			AT 242579 A	15-07-1983
			AU 523352 B2	22-07-1982
			AU 4529679 A	18-10-1979
			BG 38164 A3	15-10-1985
			CA 1140119 A1	25-01-1983
			CS 7902227 A2	12-03-1987
			CY 1250 A	31-08-1984
			DE 2961740 D1	25-02-1982
			DK 83183 A	24-02-1983
			DK 129879 A	04-10-1979
			EG 13913 A	30-09-1982
			EP 0005318 A1	14-11-1979
			ES 479206 A1	16-12-1979
			ES 8501756 A3	01-03-1985
			ES 8603463 A3	16-04-1986
			FI 791084 A ,B,	04-10-1979
			GR 64907 A1	07-06-1980
			HK 3184 A	20-01-1984
			HU 182965 B	28-03-1984
			IE 47818 B1	27-06-1984
			IL 56992 A	31-03-1983
			JP 1001477 B	11-01-1989
			JP 1523384 C	12-10-1989
			JP 54151982 A	29-11-1979
			JP 1117880 A	10-05-1989
			JP 1622522 C	25-10-1991
			JP 2040666 B	12-09-1990
			LV 5016 A3	10-06-1993
			MY 4685 A	31-12-1985
			NO 791097 A ,B,	04-10-1979
			NO 842563 A ,B,	04-10-1979

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/053606

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0005318	A	NZ 189978 A	31-05-1984
		PH 15877 A	13-04-1983
		PL 214648 A1	24-03-1980
		PT 69429 A	01-05-1979
		RO 79320 A1	17-08-1982
		SG 29883 G	19-04-1984
		SU 1056902 A3	23-11-1983
		YU 50283 A1	31-12-1983
		YU 78479 A1	31-10-1983
		ZA 7901557 A	26-11-1980
		AT 373888 B	27-02-1984
		AT 453882 A	15-07-1983
		CS 8403451 A2	12-03-1987
		KR 8300677 A	28-03-1983
WO 9201687	A	06-02-1992	
		AP 267 A	16-06-1993
		AT 171449 T	15-10-1998
		AU 644202 B2	02-12-1993
		AU 8214191 A	18-02-1992
		BG 61342 B1	30-06-1997
		BG 97314 A	18-01-1994
		CA 2086545 A1	20-01-1992
		CN 1058215 A ,C	29-01-1992
		CS 9102240 A3	19-02-1992
		DE 69130255 D1	29-10-1998
		DE 69130255 T2	08-04-1999
		WO 9201687 A1	06-02-1992
		EP 0539421 A1	05-05-1993
		ES 2121784 T3	16-12-1998
		FI 930198 A	18-01-1993
		HR 930484 A1	30-04-1996
		HU 64340 A2	28-12-1993
		IE 912532 A1	29-01-1992
		IL 98864 A	08-12-1995
		JP 3070951 B2	31-07-2000
		JP 5508839 T	09-12-1993
		KR 190299 B1	01-06-1999
		MA 22226 A1	01-04-1992
		MX 9100312 A1	28-02-1992
		NO 930156 A	18-01-1993
		NZ 238864 A	26-08-1993
		PL 297611 A1	13-07-1992
		PT 98365 A ,B	29-05-1992
		RO 111768 B1	30-01-1997
		RU 2059636 C1	10-05-1996
		SI 9111263 A	30-04-1995
		SK 278133 B6	07-02-1996
		US 5278165 A	11-01-1994
		US 5217980 A	08-06-1993
		ZA 9105653 A	31-03-1993